Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol vs Olanzapine for Cannabinoid Hyperemesis
NCT07246187Phase 3Completed
- Sponsor
- Mercy Health - St. Vincent Medical Center
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of haloperidol, olanzapine in Cannabinoid hyperemesis syndrome (CHS), sponsored by Mercy Health - St. Vincent Medical Center. Started Nov 2025; status: completed.
02
Drugs
haloperidololanzapine
03
Conditions
Cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT07246187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246187.